PFE240726C21000
- 9.40
- 0.000.00%
Pfizer Newsroom
RSV Vaccine Market to Decline 64% on CDC Decision: Report
S&P 500 Declines For Second Straight Week as Tesla, Alphabet Weigh
Market Chatter: TPG Eyes More Office Space in Manhattan
Pfizer Options Spot-On: On July 26th, 285.15K Contracts Were Traded, With 2.74 Million Open Interest
Catalyst Watch: Tech Blitz With Apple, Amazon, Microsoft, and Meta on Tap for Earnings
10 Health Care Stocks Whale Activity In Today's Session
Sangamo Rallies for Third Day in Wake of Positive Gene Therapy Results
Astellas Receives Positive CHMP Opinion For PADCEV In Combination With KEYTRUDA For First-Line Treatment Of Advanced Bladder Cancer
Pfizer Revises Incentive Plans for Employee and Shareholder Alignment
Express News | Pfizer Inc - Modifications Will Affect up to 9,000 Active Employees Holding at Least One of the Grants
Express News | Pfizer Inc - Approved Modifications to Outstanding 5-Yr Tsrus & Psas Granted in 2022 and 2023 to Eligible Active Participants
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
Investors Heavily Search Pfizer Inc. (PFE): Here Is What You Need to Know
Merck's Combination Urinary Cancer Therapy Receives EMA's Committee Nod
Bristol-Myers Gains After Q2 Beat and Late-stage Trial Win
Reduced risk of heart disease by 20%! Novo Nordisk A/S's (NVO.US) weight loss drug, Wegovy, has won a new indication in the European Union.
The European Medicines Agency (EMA) supports the use of Wegovy to reduce the risk of major cardiovascular disease and stroke in overweight or obese adults.
EC Conditionally Approves Pfizer's Haemophilia B Gene Therapy
How To Earn $100 Per Month From Pfizer Stock
Pfizer Options Spot-On: On July 25th, 837.97K Contracts Were Traded, With 2.78 Million Open Interest
Pandion Optimization Alliance Celebrates Excellence at 2nd Annual GOAT Awards